Summary Safety Review - Hydroxyzine (ATARAX and generics) - Assessing the Potential Risk of Abnormal Heart Rhythm (French, HTML)
View metadata and access the original French HTML file: Summary Safety Review - Hydroxyzine (ATARAX and generics) - Assessing the Potential Risk of Abnormal Heart Rhythm.
- Format
- HTML
- Access
- file-only
- Publisher-reported update
- 2024-05-09
A safety review was undertaken soon after the European Medicines Agency notified Health Canada of the possibility that the use of hydroxyzine products could be associated with abnormal changes in the electrical activity of the heart, such as QT interval prolongation.
Data overview
- Formats
- HTML
- File languages
- French
- Available actions
- Access original file